Bio­Marin lands three-year deal for Ger­man cov­er­age of gene ther­a­py at $900K per pa­tient

Bio­Marin an­nounced a new three-year deal on Tues­day with the Ger­man Na­tion­al As­so­ci­a­tion of Statu­to­ry Health In­sur­ance Funds (GKV-SV), which cov­ers about 90% of the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER